Drug development - September 8, 2014
BerGenBio granted platform patent
The Norwegian oncology biopharmaceutical company has announced that the United States Patent and Trademark Office (USPTO) has issued United States Patent 8,735,064 covering a method for creating and identifying functional interference RNA (RNAi) molecules. RNAis are recombinant nucleic acid molecules that have the ability to specifically down-regulate an expressed target gene in vivo. This patent protects BerGenBio’s CellSelect(TM) platform technology […]
Biotech Business - February 6, 2014
BerGenBio completes NOK75 million private placement
The oncology biopharmaceutical company announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013. According to BerGenBio proceeds from the financing will be used to support the development of the company’s portfolio of innovative cancer […]
Drug Development Pharma - December 18, 2013
BerGenBio presents promising data for CML treatment
Norwegian oncology biopharmaceutical company BerGenBio has presented results from preclinical studies on the agent BGB324 which suggest that the cancer therapy may be effective as new treatment for patients with drug resistant Chronic Myeloid Leukemia (CML). The data was presented at the Annual Meeting of the American Society of Hematology (ASH), which took place on December 7-10, […]
